Perspective Therapeutics (NYSE:CATX) Coverage Initiated by Analysts at Wedbush

Wedbush began coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research note published on Tuesday morning, MarketBeat reports. The brokerage issued an outperform rating and a $25.00 price target on the stock. Wedbush also issued estimates for Perspective Therapeutics’ Q3 2024 earnings at ($0.22) EPS, Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($0.92) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.80) EPS, FY2026 earnings at ($1.95) EPS, FY2027 earnings at ($2.03) EPS and FY2028 earnings at ($1.54) EPS.

A number of other research firms also recently weighed in on CATX. Royal Bank of Canada dropped their target price on Perspective Therapeutics from $29.00 to $27.00 and set an outperform rating for the company in a research report on Friday, August 16th. Cantor Fitzgerald restated an overweight rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Oppenheimer dropped their target price on Perspective Therapeutics from $19.00 to $17.00 and set an outperform rating for the company in a research report on Tuesday, August 13th. Truist Financial began coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They set a buy rating and a $21.00 target price for the company. Finally, Bank of America began coverage on Perspective Therapeutics in a report on Thursday, July 25th. They issued a buy rating and a $24.00 price objective for the company. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of Buy and an average price target of $20.71.

Perspective Therapeutics Trading Up 0.3 %

Perspective Therapeutics stock opened at $13.25 on Tuesday. The business has a fifty day simple moving average of $13.81. Perspective Therapeutics has a 52 week low of $2.20 and a 52 week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. Research analysts anticipate that Perspective Therapeutics will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ZWJ Investment Counsel Inc. acquired a new position in Perspective Therapeutics in the first quarter valued at about $26,000. Bleakley Financial Group LLC acquired a new position in Perspective Therapeutics in the first quarter valued at about $40,000. Victory Capital Management Inc. acquired a new position in Perspective Therapeutics in the second quarter valued at about $117,000. Point72 DIFC Ltd acquired a new position in Perspective Therapeutics in the second quarter valued at about $118,000. Finally, RIA Advisory Group LLC grew its stake in Perspective Therapeutics by 1,313.4% in the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after acquiring an additional 99,293 shares during the period. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.